课题基金 / 基金详情

T Cell Epitopes of the Malaria CS Proteins

T Cell Epitopes of the Malaria CS Proteins
疟疾 CS 蛋白的 T 细胞表位
批准号:
6772608
负责人:
Elizabeth H Nardin
金额:
$33.01万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-07-01 至 2008-01-31

项目摘要

项目成果

Elizabeth H Nardin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by the applicant): Malaria vaccines containing T and B cell epitopes of the Plasmodium falciparum circumsporozoite (CS) protein are being developed in an effort to block establishment of the pre-erythrocytic parasite stages and prevent the 200-300 million infections that occur world-wide. Phase I studies (carried out by the PI) of synthetic peptide vaccines indicate that the immune response to P. falciparum CS protein is both positively and negatively regulated by class II associated immune mechanisms. Due to their limited complexity, synthetic peptide vaccines provide unique immunogens for dissecting the genetic and cellular mechanisms that function in regulation of vaccine-induced responses. Antigen specific responses elicited by vaccines, as welt as by infectious pathogens, are initiated when dendritic cells (DC) of the innate immune system presenting capacity of DC can affect the differentiation of naive CD4+ T ceils into T helper (Th) cells that enhance humoral and cellular immunity, or CD4+ T regulatory (Tr) ceils that downregulate immune responses. Specific Aim 1 will focus on the initial cellular interactions between the innate and adaptive immune responses that are important for CS-specific CD4 T helper responses. DC from human volunteers and inbred strains of mice will be examined to determine DC from R and NR and also to examine the effect of vaccine configuration/adjuvant formulations overcome hypo-responsiveness by modulating DC function. Specific Aim 2 will examine whether CD4+ Tr cells that downregulate antibody and CD4+ T helper cells are present in non-responders to CS peptide vaccines. Specific Aim 3 will investigate protective efficacy of P. falciparum vaccine induced antibody and cellular responses using transgenic P. berghei sporozoites genetically modified to express P. falciparum CS repeats (PfPb). The availability of this unique hybrid PfPb sporozoite/murine model will facilitate (1) pre-clinical screening of humoral and cellular immunity elicited by P. falciparum vaccines and (2) evaluation of anti-P, falciparum repeat immune responses elicited in human volunteers immunized with malaria vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a topical malaria vaccine.
Malaria vaccines modified with TLR agonist adjuvant
Malaria vaccines modified with TLR agonist adjuvant
IMMUNOGENICITY OF SYNTHETIC POLYOXIME MALARIA VACCINES
海外基金